:: Volume 21, Issue 4 (Iranian South Medical Journal 2018) ::
Iran South Med J 2018, 21(4): 335-352 Back to browse issues page
Cutaneous leishmaniasis and Attempts to Con-trol it in the Contemporary Iranian History
Mohammad Hosean Alimohammadian
Immunology Dept., Pasteur Institute of Iran , mhalimoham@gmail.com
Abstract:   (828 Views)
Cutaneous leishmaniasis is a zoonotic disease caused by two species of Leishmania major and L. tropica in Iran. The disease has been known and treated in Iran by many of the most prominent Iranian physicians including Avicenna and Rhazess over the past centuries. In Qajar era, following the introduction of modern medical knowledge, and major changes in our understanding of diseases, the diagnostic and treatment methods were changed. The first new reports on this disease were provided by European physicians living in Iran. During the 1940s, some prominent Iranian researchers began to study the epidemiology, treatment and laboratory specification of the disease in different parts of the country. Due to the outbreak of the disease during the Iraq-Iran war in a dense human population (soldiers), health authorities had to try different ways to control the disease. Most importantly, soldiers were injected with live parasite vaccine. However, this procedure did not continue after the war, and immunization with inactivated vaccine replaced it and passed different phases of clinical trials. Finally, these studies were published as scientific papers. The present paper summarizes the history and control of leishmaniasis in Iran.
Keywords: Cutaneous leishmaniasis, Leishmanization, Inactivated vaccine, Leishmania major
Full-Text [PDF 689 kb]   (989 Downloads)    
Type of Study: Review | Subject: Microbiology and Immunology
Received: 2018/09/4 | Accepted: 2018/09/4 | Published: 2018/09/4
References
1. McConville MJ, De Souza D, Saunders E, et al. Living in a phagolysosome; metabolism of Leishmania amastigotes. Trends in parasitology 2007; 23(8): 368-75.
2. Mougneau E, Bihl F, Glaichenhaus N. Cell biology and immunology of Leishmania. Immunol Rev 2011; 240: 286-96.
3. Ardehali S, Rezaei HR, Nadim A. Angal Lishmania & Liashmaniouzha. Tehran: Iran University Press, 1373, 3-9. (Persian)
4. COX FE. History of human parasitology. Clin Microbiol Rev 2002; 15(4): 595-612.
5. Tajbakhsh H. History of veterinary medicine and medicine of Iran. Tehran: University of Tehran Press, 1371, 497. (Persian)
6. Polack E.J. Persien. Das Land und seine Bewohner: Ethnographische Schilderungen. Tehran: Kharazmi, 1368, 486-473. (Persian)
7. Floor W. Public Health In Qajar Iran. Canada: Mage Publishers, 2003, 39-40.
8. Ardehali S, Rezaei HR, Nadim A. Leishmania and Leishmaniasis parasites. In: Sadeghi R, editors. 2th ed. Tehran: Iran University Press, 1373, 12-200. (Persian)
9. Nadim A, Seyedi RM. A brief review of the epidemiology of various types of leishmaniasis in Iran. Acta Medica Iranica 1971; 4(8): 99-106.
10. Nadim A, Faghih MA. The epidemiology of cutaneous leishmaniasis in Isfahan province of Iran. I. the reservoir. II. the human disease. Trans R Soc Trop Med Hyg 1968; 62: 534-42.
11. Nadim A, Seyedi-Rashti MA, Mesghali A. Epidemiology of cutaneous leishmaniasis in Turkemen Sahara, Iran. J Trop Med Hyg 1968; 71(9): 238-9.
12. Javadian E, Nadim A, Tahvildare-Bidruni G, et al. Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan Part V: Report on a focus of zoonotic cutaneous leishmaniasis in Esferayen. Bull Soc Pathol Exot Filiales 1976; 69(2): 140-3.
13. Nadim A, Seyedi-Rashti MA, Faghih M. Epidemiology of cutaneous leishmaniasis in Iran. B. Khorasan. Part III. Human infection. Bull Soc Path ExotFiliales 1969; 62: 702-0.
14. Javadian E, Mesghali A. Studies on cutaneous leishmaniasis in Khuzestan, Iran. Part I. The leptomonad infection of sandflies. Bull Soc Pathol Exot Filiales 1974; 67(5): 513-6.
15. Moaddeb A, Gettner S, Ardehali S. Studies on the causative agent of cutaneous leishmaniasis in Shiraz-Iran. Iran J Med Sci 1993; 18: 28-33.
16. Sharifi I, Aflatoonian MR, Fekri AR, et al. A Comprehensive Review of Cutaneous Leishmaniasis in Kerman Province, Southeastern Iran-Narrative Review Article. Iran J Public Health 2015; 44(3): 299-307.
17. Nadim A, Javadian E, Seyedi Rashti M.A. Leishmaniasis epidemic in Iran, Angal Lishmania & Liashmaniuz-ha. Iran: Tehran,1992, 176-208. (Persian)
18. Aflatoonian MR, Sharifi I, Aflatoonian B. A Review of Impact of Bam Earthquake on Cutaneous Leishmaniasis and Status: Epidemic of Old Foci, Emergence of New Foci and Changes in Features of the Disease. J Arthropod-Borne Dis 2016; 10(3): 271–280.
19. Mahmoudzadeh-Niknam H, Ajdary S, Riazirad F, et al. Molecular epidemiology of cutaneous leishmaniasis and heterogeneity of Leishmania major strains in Iran. Trop Med Int Health 2012; 17(11): 1335-44.
20. Shirzadi, MR. A Leishmaniasis (salaak) Care Guide in Iran. Iran: Tehran, 2012, 18-21. (Persian)
21. Yaghoobi-Ershadi MR, Akhavan AA, Zahraei-Ramazani AR, et al. Field trial for the control of zoonotic cutaneous leishmaniosis in Badrood, Iran. Ann Saudi Med 2000; 20 (5-6): 386-9.
22. Yaghoobi-Ershadi MR, Moosa-Kazemi SH, Zahraei-Ramazani AR, et al. Evaluation of deltamethrin-impregnated bed nets and curtains for control of zoonotic cutaneous leishmaniasis in a hyperendemic area of Iran. Bull Soc Pathol Exot 2006; 99(1): 43-8.
23. Veysi A, Vatandoost H, Yaghoobi-Ershadi M, et al. Comparative study on the effectiveness of Coumavec® and zinc phosphide in controlling zoonotic cutaneous leishmaniasis in a hyperendemic focus in central Iran. Journal of arthropod-borne diseases 2012; 6(1): 18-27.
24. Nadim A, Javadian E, Tahvildar-Bidruni G, et al. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 1983; 76(4): 377-83.
25. Nadim A, Javadian E, Tahvildar-Bidruni G, et al. Control of zoonotic cutaneous leishmaniasis by mass leishmanization in hyperendemic area of Isfahan. MJIRI 1988; 2(2): 113-4.
26. Nicole C, Manceaux L. Recherches sur le bouton d'Orient: cultures, reproduction expérimentale, immunisation. Annales de Institute Pasteur 1910; 24: 673-720.
27. Berberian DA. Vaccination and Immunity against Oriental Sore. Trans R Soc Trop Med Hyg 1939; 33(1): 87-91.
28. Senekji HA, Beattie CP. Artificial Infection and Immunization of Man with Cultures of Leishmania tropica. Trans R Soc Trop Med Hyg 1941; 34(6): 415-419.
29. Kellina OI. Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the USSR. Bull Soc Pathol Exot Filiales 1981; 74(3): 306-18.
30. Sergiev VP. Control and prophylaxis of cutaneous leishmaniasis in the middle Asia republics of the former USSR. Bulletin de la Société française de parasitologie 1992; 10(2): 183-7.
31. Gafurov IM. Experience in controlling and preventing zoonotic cutaneous leishmaniasis in Uzbekistan. Med Parazitol (Mosk) 1999; (1): 58-9.
32. Nadim A. Research On Control Strategies for the Leist-Ttaniases. In: Walton B, Wijeyarertne PM, Modabber F, editors. Leishmanization in the Islamic Republic of Iran. International Development Research Center IDRC-MR 184e, Ottawa, 1988, 336-69.
33. Modabber F. First generation leishmaniasis vaccines in clinical development: moving, but what next. Curr Opin Investig Drugs 2000; 2: 35-9.
34. Modabber F. Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents 2010; 36 Suppl 1: S58-61.
35. Hashemi-Fesharaki R, Ale-Agha S, Habibi GR, et al. Production of inactivated wet rural Leishmania major. Iran J Med Sci 1998; 23: 74-80.
36. Alimohammadian MH, Hakimi H, Nikseresht M. The P Reparation And Evaluation Of Reference Leishmanin From Leishmania Major For Use In Man For Diagnos Tic And Experimental Purposes. MJIRI 1993; 15: 7(1): 23-8.
37. Mohebali M, Javadian EH, Hashemi-Fesharaki R, et al. Trial of a non-living crude vaccine against zoonotic cutaneous leishmaniasis. MJIRI 1995; 8(4): 211-15.
38. Farrar GH, Robinson A, Wiblin CN. Vaccine Protocols. New York: Humana Press, 1996, 251-68.
39. Dowlati Y, Ehsasi S, Shidani B, et al. Stepwise safety trial of a killed Leishmania vaccine in Iran. Clinics in Dermatology 1996; 14(5): 497-502.
40. Bahar K, Dowlati Y, Shidani B, et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol 1996; 14(5): 489-95.
41. Sharifi I, Fekri AR, Aflatonian MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351(9115): 1540-3.
42. Momeni AZ, Jalayer T, Emamjomeh M, et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17(5): 466-72.
43. Khalil EAG, El Hassan AM, Zijlstra EE, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356(9241):1565-9.
44. Alimohammadian MH, Khamesipour A, Darabi H, et al. The role of BCG in human responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine againstleishmaniasis. Vaccine 2002; 21(3-4): 174-80.
45. Kamil AA, Khalil EAG, Musa AM, et al. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003; 97(3): 365-8.
46. Modabber F. Development of vaccine against leishmaniasis. 6th International Congress of Immunology and Allergy [Brochure]; 2002 May; Iran University of Medical Sciences, Iran. Tehran: Iranian Society for Immunology and Allergy, 2002, 65.
47. Smrkovski LL, Larson CL. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun 1977; 16(1): 249-57.


XML   Persian Abstract   Print



Volume 21, Issue 4 (Iranian South Medical Journal 2018) Back to browse issues page